TRUEBLUE INC (TBI)

US89785X1019 - Common Stock

10.59  +0.06 (+0.57%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TBI. TBI was compared to 81 industry peers in the Professional Services industry. While TBI has a great health rating, there are worries on its profitability. TBI does not seem to be growing, but still is valued expensively.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

TBI had positive earnings in the past year.
In the past year TBI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: TBI reported negative net income in multiple years.
Each year in the past 5 years TBI had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of -1.58%, TBI is not doing good in the industry: 67.50% of the companies in the same industry are doing better.
TBI has a worse Return On Equity (-3.10%) than 67.50% of its industry peers.
Industry RankSector Rank
ROA -1.58%
ROE -3.1%
ROIC N/A
ROA(3y)3.5%
ROA(5y)0.32%
ROE(3y)7.32%
ROE(5y)-0.08%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 26.55%, TBI is doing worse than 71.25% of the companies in the same industry.
In the last couple of years the Gross Margin of TBI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TBI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.62%
GM growth 5Y-0.06%

More info and screens

8

2. Health

2.1 Basic Checks

TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
TBI has less shares outstanding than it did 1 year ago.
The number of shares outstanding for TBI has been reduced compared to 5 years ago.
TBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 3.47 indicates that TBI is not in any danger for bankruptcy at the moment.
The Altman-Z score of TBI (3.47) is better than 63.75% of its industry peers.
TBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.47
ROIC/WACCN/A
WACC9.27%

2.3 Liquidity

A Current Ratio of 1.74 indicates that TBI should not have too much problems paying its short term obligations.
TBI has a Current ratio of 1.74. This is in the better half of the industry: TBI outperforms 72.50% of its industry peers.
A Quick Ratio of 1.74 indicates that TBI should not have too much problems paying its short term obligations.
TBI's Quick ratio of 1.74 is fine compared to the rest of the industry. TBI outperforms 73.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74

More info and screens

3

3. Growth

3.1 Past

TBI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -85.66%.
Measured over the past years, TBI shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -31.26% on average per year.
The Revenue for TBI has decreased by -15.44% in the past year. This is quite bad
TBI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.27% yearly.
EPS 1Y (TTM)-85.66%
EPS 3Y-7.34%
EPS 5Y-31.26%
EPS growth Q2Q-81.4%
Revenue 1Y (TTM)-15.44%
Revenue growth 3Y1.07%
Revenue growth 5Y-5.27%
Revenue growth Q2Q-11.75%

3.2 Future

Based on estimates for the next years, TBI will show a very strong growth in Earnings Per Share. The EPS will grow by 29.37% on average per year.
The Revenue is expected to decrease by -3.01% on average over the next years.
EPS Next Y-133.91%
EPS Next 2Y29.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.34%
Revenue Next 2Y-3.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 30.26 indicates a quite expensive valuation of TBI.
Based on the Price/Earnings ratio, TBI is valued a bit more expensive than the industry average as 62.50% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Earnings ratio of 28.06, TBI is valued at the same level.
The Forward Price/Earnings Ratio is negative for TBI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 30.26
Fwd PE N/A

4.2 Price Multiples

66.25% of the companies in the same industry are cheaper than TBI, based on the Enterprise Value to EBITDA ratio.
TBI's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. TBI is more expensive than 70.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 104.6
EV/EBITDA 23.2

4.3 Compensation for Growth

TBI's earnings are expected to grow with 29.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRUEBLUE INC

NYSE:TBI (5/3/2024, 2:41:10 PM)

10.59

+0.06 (+0.57%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap332.42M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 30.26
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.58%
ROE -3.1%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 26.55%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-85.66%
EPS 3Y-7.34%
EPS 5Y
EPS growth Q2Q
EPS Next Y-133.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.44%
Revenue growth 3Y1.07%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y